About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 331 record(s)
Req # A-2020-001455
With respect to the listing on the Generic submissions currently under review: Abbreviated new drug submissions for the medicinal ingredient "tacrolimus", please provide any one document that would indicate the current status of the submission, such as but not limited to, an Acknowledgement Letter, Notice of Deficiency (NOD), Notice of Non-Compliance (NON), Notice of Non-Compliance Withdrawal (NON-W), or Intellectual Property (IP) Hold Letter, and any one document that would indicate the Canadian Reference Product applicable to the submission.Organization: Health Canada
March 2022
Req # A-2021-000041
All records submitted by registrant in response to Pest Management Regulatory Agency's most recent re-evaluation of sodium cyanide, specifically in response to the document titled "Subsection 16(3) Announcement of Initiation of Re-evaluation, Active Ingredient: Sodium Cyanide, Reference Number: 2021-0169, Date Sent: January 28, 202".Organization: Health Canada
March 2022
Req # A-2021-000248
A sample of the postcard(s) submitted to and/or received by Health Canada in response to the consultation document entitled “Reducing Youth Access and Appeal of Vaping Products: Consultation on Potential Regulatory Measures” published on the Government of Canada website on April 11, 2019; • one copy of letter responses for each of the five separate letter mailing campaigns and also the 305 independent submissions submitted to and/or received by Health Canada in response to the proposed Concentration of Nicotine in Vaping Products Regulations published in the Canada Gazette, Part I, Vol. 154, no 51.Organization: Health Canada
March 2022
Req # A-2021-000448
Provide copies of the credit card statements for the defaulted cards referred to in Sessional Paper 8555-432-675, tabled in the House of Commons on June 14, 2021. Limit timeframe of records from January 1, 2017 to June 21, 2021.Organization: Health Canada
March 2022
Req # A-2021-000783
Documents that address Health Canada protocols for interception or seizure of psilocybin, including, but not limited to, agency protocols for: training related to the seizure of psilocybin, search, notification, testing, storage, destruction, return or forfeiture. Timeline: JUL 1 2018 to AUG 25 2021.Organization: Health Canada
March 2022
Req # A-2021-001017
Subsequent request to A-2021-000734 from the list provided by the Office of Primary Interest, please provide a random sampling of 20 manufacturers including: Active Class II Medical Device Licence numbers, device name and producer or manufacturer using the scope statement of the associated Quality Management Systems (QMS) certificate containing the word “design”.Organization: Health Canada
March 2022
Req # A-2021-001121
Obtain information regarding the status of the Health Canada file on this company: JSS Medical Research Inc. (NEQ: 1171208623), 9400 Henri-Bourassa Blvd. West, Montreal, Quebec, H4S 1N8.Organization: Health Canada
March 2022
Req # A-2021-001217
All comments received by the department relating to the draft Screening Level Risk Assessment for the Monocyclic and bicyclic Sesquiterpenes Group.Organization: Health Canada
March 2022
Req # A-2021-001234
Advise whether the Abbreviated New Drug Submission (ANDS) for degarelix acetate has received either: a Notice of Deficiency (NOD); a Notice of Non-Compliance (NON); a NOD-Withdrawal (NOD-W); or a NON-Withdrawal (NON-W). If the ANDS has received any of these notices: advise of the month and year that the notice was issued; and provide a copy of the correspondence.Organization: Health Canada
March 2022
Req # A-2021-001237
Provide the name of the company (sponsor) who submitted the Abbreviated New Drug Submission (ANDS) for degarelix acetate, which was accepted into review on or after October 1, 2018.Organization: Health Canada
March 2022